
Injectable, Structural Regenerative Implant for Cartilage Care
Protect • Repair • Regenerate
Cartilage injuries can turn simple movement into a challenge. Without timely treatment, damage may progress and increase the risk of arthritis or future joint replacement.
At Liquid Cartilage, our goal is joint preservation and regeneration—not replacement. With ChondroFiller®, we deliver advanced, evidence-led care on Harley Street.

Cartilage provides the smooth, low-friction surface that lets your joints move comfortably. It doesn’t readily self-repair, but with the right scaffold and biological cues, regeneration is possible.
Act early to preserve more of what you have.

ChondroFiller® is an acellular, biologic collagen scaffold delivered in liquid form. Once placed, it gels within minutes, filling the defect and providing a framework that invites your cells to rebuild cartilage.
Think of it like “epoxy” for cartilage—without the plastic.
One treatment. One step. A chance to keep your joint for the long term.


ChondroFiller® sits in a different class— structural regenerative implant.
| Treatment | Analogy | What it Does | Limitation |
|---|---|---|---|
| HA (Hyaluronic Acid) | WD-40 | Improves lubrication for short-term comfort | Temporary; does not regenerate tissue |
| Arthrosamid® | Silicone | Acts on the synovium to reduce pain signalling | Not regenerative; literature notes complication rates up to 30% |
| ChondroFiller® | Epoxy resin | Fills defects, stabilises, and promotes true cartilage repair | Most robust injectable option for structural repair |
ChondroFiller®: our structural, regenerative approach to focal cartilage defects.
Small joints: thumb, fingers, elbow, AC joint, toes, TMJ…
From £2,100
Large joints: knee, hip, shoulder, ankle
From £2,800
Best for knee, hip, shoulder
From £6,500 (knee), £9,500 (hip/shoulder)
Our proprietary MSC Co-Delivery Technique
Introductory offer: your consultation fee is credited toward treatment if you proceed.

Quick, no-obligation chat

Comprehensive assessment with Prof. Paul Lee

Injection, Keyhole, or Liquid Cartilage™

Precise and minimally invasive



Cartilage damage won’t reverse on its own—yet with the right plan it can be protected, repaired, and regenerated.
At Liquid Cartilage, you access world-leading science and a joint-preservation vision on Harley Street.
(Consultation fee credited towards treatment if you proceed.)
Everything you want to know about ChondroFiller® at Liquid Cartilage.
ChondroFiller® is an acellular collagen gel that fills cartilage defects and forms a scaffold for your own cells to regenerate healthy tissue. Unlike temporary injections, it supports hyaline-like restoration for smoother motion and protection long-term.
HA or Arthrosamid® may give short-term pain relief, while ChondroFiller® aims to rebuild cartilage. Compared with replacement, it preserves your natural joint and avoids prosthesis risks. Our approach is regenerate-first.
Studies show +30 IKDC in knees, +33 Harris Hip Score in hips, and improved ankle metrics. MRI (MOCART) typically reads 70–87. Globally, >19,000 cases support safety and function.
Best for focal defects up to 6 cm² in knees, hips, ankles, or small joints. Active younger patients often benefit, but older patients may qualify if surrounding cartilage is stable.
Delivered via precise injection or keyhole surgery. The gel sets in minutes. Expect partial weight-bearing ~6 weeks, steady return to cycling/swimming, and most sports around ~12 months alongside specialist rehab.
Harley Street location; UK ICRS Centre of Excellence. Led by Prof. Paul Lee, with advanced options like Liquid Cartilage™ (ChondroFiller® + cells) to prioritise preservation.
Discover what makes ChondroFiller® unique at Liquid Cartilage.

For focal osteochondral lesions of the talus larger than 15 mm, bone marrow stimulation alone succeeds only 3% of the time; ChondroFiller, an injectable collagen scaffold placed under ultrasound guidance, offers a non-surgical pathway using the patient's own repair cells—no general anaesthetic or surgical incision.

Night pain, progressive loss of walking distance, and mechanical symptoms such as catching or locking signal that conservative management of hip osteoarthritis has run its course.

The choice between OATS and MACI for cartilage repair turns on a single measurement: lesion surface area. OATS is standard for defects under 2 cm², MACI for those above 4 cm², with equivalent outcomes in the 2–4 cm² range.

ChondroFiller is an acellular collagen scaffold that self-polymerises in the hip joint, recruiting progenitor cells to form repair tissue over three to six months; it achieves good outcomes in focal cartilage defects with preserved joint space but fails in advanced osteoarthritis.

Anterior knee pain does not reliably indicate cartilage damage; symptoms correlate only loosely with structural grade, requiring imaging and functional testing for accurate diagnosis.

NICE restricts MACI to patients meeting all four criteria simultaneously — a defect larger than 2 cm², no prior cartilage surgery, minimal osteoarthritis, and referral to a tertiary centre — whilst ChondroFiller injection has no such gates, serving largely different populations.